Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

Julia C. Greenland; Kerry Dresser; Emma Cutting; Rachel Donegan; Simon Bond; Sarah Crisp; Kirsten M. Scott; Zanna J. Voysey; Jonathan Holbrook; Lakmini Kahanawita; Reiss Pal; Marta Camacho; Alexander R. D. Peattie; Lennart R. B. Spindler; Young T. Hong; Tim D. Fryer; Caroline H. Williams‐Gray

doi:10.1016/s1474-4422(25)00386-2

Related Publications

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Bruce Neal , Vlado Perkovic , Dick de Zeeuw +9 more

Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered ...

2013 American Heart Journal 330 citations

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein , Helen M. Colhoun , Gilles R. Dagenais +97 more

This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had eit...

2019 The Lancet 2683 citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang , Gang Zeng , Hongxing Pan +17 more

With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Scie...

2020 The Lancet Infectious Diseases 1488 citations

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

David Devos , Caroline Moreau , Jean Christophe Devedjian +27 more

The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-...

2013 Antioxidants and Redox Signaling 593 citations

Publication Info

Year: 2025
Type: article
Volume: 25
Issue: 1
Pages: 39-49
Citations: 1
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Julia C. Greenland, 
                                
                                    Kerry Dresser, 
                                
                                    Emma Cutting
                                
                                et al.
                            
                            (2025). 
                            Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. 
                            The Lancet Neurology
                            , 25
                            (1)
                            , 39-49.
                            https://doi.org/10.1016/s1474-4422(25)00386-2
                        

Identifiers

DOI: 10.1016/s1474-4422(25)00386-2